One of the biggest challenges in cancer treatment is identifying the chemotherapy regimen that is most likely to work in a particular patient. Caner being a highly heterogeneous disease, chemotherapy response varies widely from patient to patient, even for the same type of cancer. Trial-and-error remains the norm, particularly with chemotherapy, leading to ineffective treatments at high cost and significant avoidable side effects. Oncosense is a novel diagnostic test designed to identify the best drug or combination of drug that is likely to work in a patient and those that are not likely to work. The test helps to move the experimentation for identifying the most effective drug from the patient to the laboratory. The key feature of the test is that it monitors the broad molecular landscape of the tumor responsible for chemoresistance or chemosensitivity and does not rely on single markers. Single markers, when it exists, are notorious for having low predictive value because cancer cells use multiple pathways to attain resistance to drugs. The test screens for the activity of 96-192 genes which allows one to predict the sensitivity or resistance to various chemotherapeutics. Oncosense is a truly revolutionary test which addresses a large unmet need in oncology i.e. identification of the drug that has the most chance of working in a particular patient. A small clinical trial has shown that lung cancer patients who received Oncosence test-guided chemotherapy lived twice as long as those who received chemotherapy based conventional decision-making (Oncosense-guided therapy vs. physician’s choice therapy). Over 1000 patient samples have been analyzed so far and very good correlation with chemosensitivity/resistance has been established. The test has been shown to be effective for most solid tumors including lung, breast, ovarian, melanoma, colorectal, upper GI, cervical etc. The Company has developed a new panel which is based on the original invention by Prof Ian Cree (Taqman Array) which has been further modified significantly to improve predictability. The test uses a proprietary algorithm to convert the gene expression pattern into easy to understand drug sensitivity scores. The test requires merely a few tumor cells and formalin fixed paraffin embedded tissue biopsies are compatible with the test providing it wider utility and ease of use. It is a real-time PCR array-based test.